home→Diagnostics→ Lindinet 20 after 30. Lindinet birth control pills

Lindinet 20 after 30. Lindinet birth control pills

In this article, you can read the instructions for use medicinal product Lindinet 20 and 30. Reviews of site visitors - consumers of this medicine, as well as opinions of specialist doctors on the use of Lindinet in their practice are presented. A big request to actively add your reviews about the drug: did the medicine help or not help get rid of the disease, what complications and side effects were observed, perhaps not declared by the manufacturer in the annotation. Lindinet analogs in the presence of existing structural analogs. Use of hormonal birth control for contraception in women, including during pregnancy and breastfeeding. Side effects(bleeding, pain).

Lindinet- monophasic oral contraceptive. It inhibits the secretion of gonadotropic hormones from the pituitary gland. The contraceptive effect of the drug is associated with several mechanisms. The estrogenic component of the drug is ethinylestradiol, a synthetic analogue of the follicular hormone estradiol, which, together with the corpus luteum hormone, participates in the regulation of the menstrual cycle. The progestogen component is gestodene, a derivative of 19-nortestosterone, which is superior in strength and selectivity of action not only to the natural corpus luteum hormone progesterone, but also to other synthetic progestogens (for example, levonorgestrel). Due to its high activity, gestodene is used in low dosages, in which it does not exhibit androgenic properties and has practically no effect on lipid and carbohydrate metabolism.

Along with the indicated central and peripheral mechanisms that prevent the maturation of an egg capable of fertilization, the contraceptive effect is due to a decrease in the susceptibility of the endometrium to the blastocyst, as well as an increase in the viscosity of the mucus in the cervix, which makes it relatively impassable for spermatozoa. In addition to the contraceptive effect, the drug, when taken regularly, also has a therapeutic effect, normalizing menstrual cycle and helping to prevent the development of a number of gynecological diseases, incl. tumor nature.

The difference between Lindinet 20 and Lindinet 30

The main difference between both drugs lies in the different amounts of ethinylestradiol included in the component in one type of drug it contains 30 mcg, in the other 20 mcg. Hence the various names of similar nevertheless preparations. Also in the composition of both preparations there is gestodene in the amount of 75 mcg.

Pharmacokinetics

Gestodene

After oral administration, it is rapidly and completely absorbed from the gastrointestinal tract. Bioavailability - about 99%. Gestodene is biotransformed in the liver. It is excreted only in the form of metabolites, 60% - with urine, 40% - with feces.

Ethinylestradiol

After oral administration, ethinylestradiol is absorbed rapidly and almost completely. Ethinylestradiol is excreted only in the form of metabolites, in a ratio of 2:3 with urine and bile.

Indications

contraception.

Release form

Coated tablets.

Instructions for use and regimen

Assign 1 tablet per day for 21 days, if possible at the same time of day. After taking the last tablet from the package, a 7-day break is taken, during which withdrawal bleeding occurs. The next day after a 7-day break (i.e. 4 weeks after taking the first tablet, on the same day of the week), the drug is resumed.

The first tablet of Lindinet should be taken from the 1st to the 5th day of the menstrual cycle.

When switching to Lindinet from another combined oral contraceptive, the first Lindinet tablet should be taken after taking the last pill from the package of another oral hormonal contraceptive, on the first day of withdrawal bleeding.

When switching to Lindinet from drugs containing only progestogen ("mini-pill", injections, implant), when taking "mini-pill", Lindinet can be taken on any day of the cycle, you can switch from using an implant to taking Lindinet on the next day after the removal of the implant, when using injections - on the eve of the last injection. In these cases, additional methods of contraception should be used in the first 7 days.

After an abortion in the 1st trimester of pregnancy, you can start taking Lindinet immediately after surgery. In this case, there is no need to use additional methods of contraception.

After childbirth or after an abortion in the 2nd trimester of pregnancy, the drug can be taken on the 21-28th day. In these cases, additional methods of contraception must be used in the first 7 days. With a later start of taking the drug in the first 7 days, an additional, barrier method of contraception should be used. In the case when sexual contact took place before the start of contraception, before starting the drug, pregnancy should be excluded or the start of the drug should be postponed until the first menstruation.

If you miss a pill, you should take the missed pill as soon as possible. If the interval in taking the tablets was less than 12 hours, then the contraceptive effect of the drug does not decrease, and in this case there is no need to use an additional method of contraception. The remaining tablets should be taken at the usual time. If the interval was more than 12 hours, then the contraceptive effect of the drug may decrease. In such cases, you should not make up for the missed dose, continue taking the drug as usual, but in the next 7 days, you need to use an additional method of contraception. If at the same time there are less than 7 tablets left in the package, the drug from the next package should be started without interruption. In this case, withdrawal bleeding does not occur until the completion of the second pack, but spotting or breakthrough bleeding may occur.

If withdrawal bleeding does not occur after the end of taking the drug from the second package, then pregnancy should be excluded before continuing to take the drug.

If vomiting and / or diarrhea begins within 3-4 hours after taking the drug, the contraceptive effect may decrease. In such cases, you should proceed in accordance with the instructions for skipping pills. If the patient does not want to deviate from the usual contraceptive regimen, the missed pills should be taken from another package.

To accelerate the onset of menstruation, you should reduce the break in taking the drug. The shorter the break, the more likely the occurrence of breakthrough or spotting bleeding while taking the pills from the next pack (similar to cases with delayed menstruation).

To delay the onset of menstruation, the drug should be continued from a new package without a 7-day break. Menstruation can be delayed as long as necessary until the end of the last pill from the second package. With a delay in menstruation, breakthrough or spotting bleeding may occur. Regular use of the drug Lindinet can be restored after the usual 7-day break.

Side effect

Side effects requiring discontinuation of the drug:

arterial hypertension;
arterial and venous thromboembolism (including myocardial infarction, stroke, deep vein thrombosis of the lower extremities, pulmonary embolism);
arterial or venous thromboembolism of the hepatic, mesenteric, renal, retinal arteries and veins;
hearing loss due to otosclerosis;
hemolytic-uremic syndrome;
porphyria;
exacerbation of reactive systemic lupus erythematosus;
Sydenham's chorea (passing after discontinuation of the drug).

Other side effects (less severe):

acyclic bleeding/ bloody issues from the vagina;
amenorrhea after discontinuation of the drug;
change in the state of vaginal mucus;
development of inflammatory processes of the vagina;
candidiasis;
tension, pain, breast enlargement;
galactorrhea;
pain in the epigastrium;
nausea, vomiting;
Crohn's disease;
ulcerative colitis;
the occurrence or exacerbation of jaundice and / or itching associated with cholestasis;
liver adenoma;
erythema nodosum;
exudative erythema;
rash;
chloasma;
increased hair loss;
headache;
migraine;
mood lability;
depression;
hearing loss;
increased sensitivity of the cornea (when wearing contact lenses);
fluid retention in the body;
change (increase) in body weight;
decreased tolerance to carbohydrates;
hyperglycemia;
allergic reactions.

Contraindications

the presence of severe and / or multiple risk factors for venous or arterial thrombosis (including complicated lesions of the valvular apparatus of the heart, atrial fibrillation, diseases of the cerebral vessels or coronary arteries, severe or moderate arterial hypertension with blood pressure ≥ 160/100 mm Hg .st.);
the presence or indication in the anamnesis of the precursors of thrombosis (including transient ischemic attack, angina pectoris);
migraine with focal neurological symptoms, incl. in history;
venous or arterial thrombosis / thromboembolism (including myocardial infarction, stroke, deep vein thrombosis of the lower leg, pulmonary embolism) at present or in history;
the presence of venous thromboembolism in history;
surgery with prolonged immobilization;
diabetes(with angiopathy);
pancreatitis (including history), accompanied by severe hypertriglyceridemia;
dyslipidemia;
severe liver disease, cholestatic jaundice (including during pregnancy), hepatitis, incl. in history (before the normalization of functional and laboratory parameters and within 3 months after their normalization);
jaundice when taking GCS;
cholelithiasis at present or in history;
Gilbert's syndrome, Dubin-Johnson syndrome, Rotor's syndrome;
liver tumors (including history);
severe itching, otosclerosis or its progression during a previous pregnancy or taking corticosteroids;
hormone-dependent malignant neoplasms of the genital organs and mammary glands (including if they are suspected);
vaginal bleeding of unknown etiology;
smoking over the age of 35 (more than 15 cigarettes per day);
pregnancy or suspicion of it;
lactation period;
hypersensitivity to the components of the drug.

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy and lactation.

In small quantities, the components of the drug are excreted in breast milk.

When used during lactation, milk production may decrease.

special instructions

Before starting the use of the drug, it is necessary to conduct a general medical (detailed family and personal history, measurement of blood pressure, laboratory tests) and gynecological examination (including examination of the mammary glands, pelvic organs, cytological analysis of a cervical smear). A similar examination during the period of taking the drug is carried out regularly, every 6 months.

The drug is a reliable contraceptive: the Pearl index (an indicator of the number of pregnancies that occurred during the use of a contraceptive method in 100 women for 1 year) with correct application is about 0.05. Due to the fact that the contraceptive effect of the drug from the start of taking is fully manifested by the 14th day, in the first 2 weeks of taking the drug, it is recommended to additionally use non-hormonal methods of contraception.

In each case, before prescribing hormonal contraceptives, the benefits or possible negative effects of their use are individually assessed. This issue must be discussed with the patient, who, after receiving the necessary information, will make the final decision on the preference for hormonal or any other method of contraception.

The state of health of women must be carefully monitored. If any of the following conditions / diseases appear or worsen while taking the drug, you must stop taking the drug and switch to another, non-hormonal method of contraception:

diseases of the hemostasis system;
conditions/diseases predisposing to the development of cardiovascular, renal failure;
epilepsy;
migraine;
the risk of developing an estrogen-dependent tumor or estrogen-dependent gynecological diseases;
diabetes mellitus, not complicated by vascular disorders;
severe depression (if depression is associated with impaired tryptophan metabolism, then vitamin B6 can be used to correct it);
sickle cell anemia, tk. in some cases (for example, infections, hypoxia), estrogen-containing drugs in this pathology can provoke thromboembolism;
the appearance of abnormalities in laboratory tests for assessing liver function.

Thromboembolic diseases

Epidemiological studies have shown that there is a link between taking oral hormonal contraceptives and an increased risk of developing arterial and venous thromboembolic diseases (including myocardial infarction, stroke, deep vein thrombosis of the lower extremities, pulmonary embolism). An increased risk of venous thromboembolic disease has been proven, but it is significantly less than during pregnancy (60 cases per 100,000 pregnancies). When using oral contraceptives, arterial or venous thromboembolism of the hepatic, mesenteric, renal or retinal vessels is very rarely observed.

The risk of developing arterial or venous thromboembolic diseases increases:

with age;
when smoking (heavy smoking and age over 35 are risk factors);
if there is a family history of thromboembolic diseases (for example, in parents, a brother or sister). If a genetic predisposition is suspected, it is necessary to consult a specialist before using the drug;
with obesity (body mass index over 30 kg/m2);
with dyslipoproteinemia;
with arterial hypertension;
in diseases of the heart valves, complicated by hemodynamic disorders;
with atrial fibrillation;
with diabetes mellitus complicated by vascular lesions;
with prolonged immobilization, after major surgery, after surgery on lower limbs after a severe injury.

In these cases, a temporary discontinuation of the drug is expected (no later than 4 weeks before surgery, and resumed no earlier than 2 weeks after remobilization).

Women after childbirth have an increased risk of venous thromboembolic disease.

It should be borne in mind that diabetes mellitus, systemic lupus erythematosus, hemolytic uremic syndrome, Crohn's disease, ulcerative colitis, sickle cell anemia, increase the risk of developing venous thromboembolic diseases.

It should be borne in mind that resistance to activated protein C, hyperhomocysteinemia, deficiency of proteins C and S, deficiency of antithrombin 3, the presence of antiphospholipid antibodies increase the risk of developing arterial or venous thromboembolic diseases.

When assessing the benefit / risk ratio of taking the drug, it should be taken into account that targeted treatment of this condition reduces the risk of thromboembolism. The symptoms of thromboembolism are:

sudden chest pain that radiates to left hand;
sudden shortness of breath;
any unusually severe headache that lasts for a long time or appears for the first time, especially when combined with sudden complete or partial loss of vision or diplopia, aphasia, dizziness, collapse, focal epilepsy, weakness or severe numbness of one half of the body, movement disorders, severe unilateral pain in the calf muscle, acute abdomen.

Tumor diseases

Some studies have reported an increase in the occurrence of cervical cancer in women who have been taking hormonal contraceptives for a long time, but the results of the studies are conflicting. Sexual behavior, human papillomavirus infection and other factors play a significant role in the development of cervical cancer.

A meta-analysis of 54 epidemiological studies showed that there is a relative increase in the risk of breast cancer among women taking oral hormonal contraceptives, but the higher detection of breast cancer could be associated with more regular medical examinations. Breast cancer is rare among women under 40, whether they are taking hormonal birth control or not, and increases with age. Taking pills can be regarded as one of many risk factors. However, women should be advised of the potential risk of developing breast cancer based on a benefit-risk assessment (protection against ovarian and endometrial cancer).

There are few reports of the development of benign or malignant liver tumors in women who take hormonal contraceptives for a long time. This should be kept in mind in the differential diagnostic evaluation of abdominal pain, which may be associated with an increase in the size of the liver or intraperitoneal bleeding.

Chloasma

Chloasma can develop in women who have a history of this disease during pregnancy. Those women who are at risk of developing chloasma should avoid contact with the sun's rays or ultraviolet radiation while taking Lindinet.

Efficiency

The effectiveness of the drug may decrease in the following cases: missed pills, vomiting and diarrhea, simultaneous use of other drugs that reduce the effectiveness of birth control pills.

If the patient is simultaneously taking another drug that can reduce the effectiveness of birth control pills, additional methods of contraception should be used.

The effectiveness of the drug may decrease if, after several months of their use, irregular, spotting or breakthrough bleeding appears, in such cases it is advisable to continue taking the tablets until they are finished in the next package. If, at the end of the second cycle, menstrual bleeding does not begin or acyclic spotting does not stop, stop taking the tablets and resume it only after pregnancy has been excluded.

Changes in laboratory parameters

Under the influence of oral contraceptive pills - due to the estrogen component - the level of some laboratory parameters (functional parameters of the liver, kidneys, adrenal glands, thyroid gland, indicators of hemostasis, levels of lipoproteins and transport proteins).

Additional Information

After acute viral hepatitis, the drug should be taken after normalization of liver function (not earlier than after 6 months).

With diarrhea or intestinal disorders, vomiting, the contraceptive effect may decrease. Without stopping taking the drug, it is necessary to use additional non-hormonal methods of contraception.

Women who smoke have an increased risk of developing vascular diseases with serious consequences (myocardial infarction, stroke). The risk depends on age (especially in women over 35) and on the number of cigarettes smoked.

A woman should be warned that the drug does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Influence on the ability to drive vehicles and control mechanisms

Studies on the effect of the drug Lindinet on the ability to drive a car and work machinery have not been conducted.

drug interaction

The contraceptive activity of Lindinet is reduced when taken simultaneously with ampicillin, tetracycline, rifampicin, barbiturates, primidone, carbamazepine, phenylbutazone, phenytoin, griseofulvin, topiramate, felbamate, oxcarbazepine. The contraceptive effect of oral contraceptives is reduced with the use of these combinations, breakthrough bleeding and menstrual disorders become more frequent. While taking Lindinet with the above drugs, as well as within 7 days after completing the course of taking them, it is necessary to use additional non-hormonal (condom, spermicidal gels) methods of contraception. When using rifampicin, additional methods of contraception should be used within 4 weeks after completion of the course of its administration.

When used simultaneously with Lindinet, any drug that increases gastrointestinal motility reduces absorption active substances and their plasma levels.

Sulfation of ethinyl estradiol occurs in the intestinal wall. Drugs that also undergo sulfation in the intestinal wall (including ascorbic acid) competitively inhibit the sulfation of ethinylestradiol and thereby increase the bioavailability of ethinylestradiol.

Inducers of microsomal liver enzymes reduce the level of ethinylestradiol in blood plasma (rifampicin, barbiturates, phenylbutazone, phenytoin, griseofulvin, topiramate, hydantoin, felbamate, rifabutin, oscarbazepine). Liver enzyme inhibitors (itraconazole, fluconazole) increase plasma levels of ethinylestradiol.

Some antibiotics (ampicillin, tetracycline), preventing the intrahepatic circulation of estrogens, reduce the level of ethinylestradiol in plasma.

Ethinylestradiol, by inhibiting liver enzymes or accelerating conjugation (primarily glucuronidation), can affect the metabolism of other drugs (including cyclosporine, theophylline); the concentration of these drugs in the blood plasma may increase or decrease.

With the simultaneous use of Lindinet with St. John's wort (including infusion), the concentration of active substances in the blood decreases, which can lead to breakthrough bleeding, pregnancy. The reason for this is the inducing effect of St. John's wort on liver enzymes, which continues for another 2 weeks after the completion of the course of taking St. John's wort. This combination of drugs is not recommended.

Ritonavir reduces the AUC of ethinylestradiol by 41%. In this regard, during the use of ritonavir, a hormonal contraceptive with a higher content of ethinylestradiol (Lindinet 30) should be used or additional non-hormonal methods of contraception should be used.

It may be necessary to correct the dosing regimen when using hypoglycemic agents, tk. oral contraceptives may reduce carbohydrate tolerance, increase the need for insulin or oral antidiabetic agents.

Lindinet's analogues

Structural analogues for the active substance:

Logest;
Mirelle;
Femoden.

In the absence of analogues of the drug for the active substance, you can follow the links below to the diseases that the corresponding drug helps with and see the available analogues for the therapeutic effect.

Monophasic oral contraceptive. Inhibits the secretion of gonadotropins. The mechanism of contraception is provided in several ways. The estrogenic component in the drug ethinylestradiol, which is a synthetic analogue of estradiol. The progestogen component is gestodene, which is a derivative of 19-nortestosterone. This type of gestagen is more active than other synthetic gestagens, which allows it to be used in lower dosages, so the effect on carbohydrate and lipid metabolism is minimal.

The main mechanism of action is an obstacle to the maturation of the egg, another mechanism is a decrease in the sensitivity of the endometrium to the blastocyst, in addition, the viscosity of the mucus in the cervical canal increases and the peristalsis of the fallopian tubes decreases.

Along with the contraceptive effect, Lindinet has a therapeutic effect, normalizing the menstrual cycle.

The difference between Lindinet 20 and Lindinet 30 preparations is in the amount of estrogen content. One contains 20 mcg, and the other 30 mcg. Gestodene in both preparations, 75 mcg.

Indications

Contraception

Contraindications

arterial hypertension of moderate and severe severity
atrial fibrillation
cerebrovascular accident
history of thromboembolism
history of ischemic attack
history of angina pectoris
migraine with a history of neurological symptoms
surgical treatment, accompanied by prolonged immobilization
diabetes mellitus with angiopathy
pancreatitis
lipid metabolism disorder
cholestasis
Gilbert's syndrome
Dubin-Jones syndrome
Rotor syndrome
current and past history of liver tumor
itchy skin from a previous pregnancy
hormone-dependent neoplasms of the mammary glands and genital organs
spotting from the vagina of unknown origin
smoking more than 10 cigarettes a day
pregnancy
lactation
individual intolerance to the components of the drug

Mode of application

1 tablet daily at the same time of day for 21 days. Then they take a break of 7 days. During this period, there will be withdrawal bleeding - a menstrual-like reaction. On the 8th day, start taking a new package. This reception mode is called 21+7.

The first dose of the drug is started from the 1st day of the menstrual cycle (that is, from the 1st day of the menstruation), it is permissible to start the first tablet from the 1st to the 5th day of the menstrual cycle.

If you have to switch from purely progestin drugs to Lindinet, then you can take Lindinet on any day of the cycle. The transition from the implant to the use of Lindinet is carried out immediately after the removal of the implant. When switching from injectable contraception to Lindinet, start taking it before the last injection and use additional contraception for 7 days.

After an abortion, the drug is started on the day of the procedure. Additional contraception in this case is not needed.

After childbirth or after an abortion in the 2nd trimester, the drug is taken on days 21-28, additional contraception must be used for 7 days.

If one tablet is missed, then the missed tablet should be taken immediately, as soon as the missed one was remembered, the next tablet is taken according to the schedule. The contraceptive effect is not reduced if less than 12 hours have passed since the missed. If more than 12 hours have passed, then additional barrier contraception is needed within a week.

If it is necessary to postpone the beginning of the next menstruation, then there is no seven-day break between the concurrencies. At the end of one convalescence with 21 tablets, a new concurrency is started. Menstruation can be delayed for as long as needed. With continuous use of the drug, breakthrough bleeding may occur.

If withdrawal bleeding does not occur within a seven-day break, then pregnancy must be excluded.

The contraceptive effect is reduced if vomiting or diarrhea occurs within 3-4 hours after taking the pill. You need to take an extra pill. Then take according to the schedule.

If you need to bring the date of menstruation closer, then simply stop taking the pills before 21 days.

Additionally

Side effects

Cancellation of the drug requires the following conditions:

Arterial hypertension
Thromboembolism arterial and venous
Thromboembolism of the mesenteric, hepatic or renal veins or arteries.
hearing loss
porfiria
Systemic lupus erythematosus in exacerbation
Sydenham's chorea

Side effects that do not require urgent discontinuation of the drug:

Amenorrhea after discontinuation of Lindinet
Bloody acyclic discharge from the vagina
Candidiasis Mastalgia
Galactorrhea
Vomit
Nausea
Crohn's disease
ulcerative colitis
cholestatic jaundice
Liver hemangioma
Erythema nodosum
Chloasma
Hair Loss
Migraine
depressive states
Emotional lability
Edema
hyperglycemia
allergic reactions

Before you start taking Lindinet 20 or 30, you must undergo a general clinical and gynecological examination with a mandatory examination of the mammary glands and taking a cytological smear from the cervix. Further, such an examination is carried out once every six months.

Lindinet 20 and 30 is a highly effective contraceptive, and when used correctly, the Pearl Index is 0.05.

The benefits and risks of using hormonal contraception are individually assessed, the woman's reproductive plans and her preferences in contraceptive methods are identified.

Strict monitoring of a woman's health is required while taking hormonal contraception. If any of the following conditions worsen during hormonal contraception, it is recommended to switch to another method of contraception:

violation of the hemostasis system
risk of developing a hormone-dependent tumor
diabetes
sickle cell anemia
liver laboratory abnormalities

Thromboembolic complications increase in the presence of the following factors:

with age
smoking
family history of thromboembolism
obesity
dyslipoproteinemia
arterial hypertension
cardiac pathology with hemodynamic disorders
fibrillation
prolonged immobilization due to surgery
the presence of antiphospholipid antibodies

Symptoms of thromboembolism:

Sudden onset chest pain radiating to the left arm
Sudden onset of shortness of breath
unusual strong pain, which appeared for the first time

All of these symptoms are grounds for immediate medical attention. medical care and immediate discontinuation of the drug.

The effectiveness of the drug is reduced in the following cases:

Missing a pill
Vomit
Diarrhea
Combination with drugs that reduce the effectiveness of COCs
If after long-term use appear acyclic spotting spotting

After suffering viral hepatitis, hormonal contraception can be started no earlier than 6 months later.

With vomiting, diarrhea, the contraceptive effect may decrease, so it is not necessary to stop taking the drug, but after an episode of these conditions, additional contraception is necessary for 7 days.

The drug does not protect against HIV infection and other STIs, therefore, if a woman has several sexual partners, then she needs to additionally use a condom.

Lindinet does not affect concentration.

Drugs that reduce the effectiveness of Lindinet:

Ampicillin
Pyramidon
Barbiturates
Tetracycline
Phenytoin
Topiramate
Karmazepin
Phenylbutazone
Griseofulvin
Felbamate
Oxcarzepine
When these drugs are combined with Lindinet, additional barrier contraception is required for 7 days after taking the listed drugs, and when treated with rifampicin, barrier contraception should be used for another 4 weeks after the end of treatment.

I have been using Lindinet for a long time, for me it is the best type of contraception! Very convenient and how nice))

I started with Lindinet 20, but then there was some kind of failure after the cancellation, most likely the dose of the hormone was low, and I had to switch to Lindinet 30. What can I say about the differences? it hurts. Sometimes it hurts a lot, sometimes not so much, but still better than before taking contraceptives. Then I couldn’t get out of bed at all.

Do you know what is the huge plus of this tool for me? Discharge during menstruation is minimal! I don’t buy pads at all, I use daily ones. Menstruation lasts 3 days, just a few drops a day.

Second plus: if for some reason you need to prevent menstruation, then it is very simple to do this: after drinking 21 tablets, you do not take a seven-day break, but start drinking the next pack right away. I do this periodically, there were no problems. PMS on the days of the expected menstruation does not bother either. In general, it is very very convenient. You need to be prepared that when the menstruation does come (at the end of the second pack), they can be more abundant than usual.

Dear girls! If you decide to use hormonal contraceptives, be prepared for the fact that you may not be able to make love without lubrication! As a lubricant, I use this and that. Just do not try to combine the first with condoms! Unless, of course, you want a baby.

I do not attach the instruction, because it is HUGE! You can find it on the Internet

I will include only the most important.

And now I’ll tell you how I once bought Lindinet 30. So I decided to buy myself 3 packs, in reserve. I went to one of the cheapest pharmacies, bought 1 pack for 543 rubles. I thought it was a little expensive, so I didn’t buy 2 more .And in the evening, when I was walking with my beloved, I looked into another pharmacy, and there ... There one pack (from one batch) cost 327 rubles, but this pack was the last, and they gave me another (from another batch) it cost 407 r .. Here is such a fun in our pharmacies!

So do not rush to take it right away, it is better to find out the price of the medicine in different pharmacies.

All successful shopping and quality sex!)))))

"Lindinet 20" is a combination drug produced in the form of tablets. It has a contraceptive effect and is used for planned, regular contraception. The composition includes gestodene and ethinylestradiol, which in combination provide a reliable contraceptive effect. The drug inhibits the pituitary secretion of gonadotropins due to the action of estrogen-gestagens. The components of the drug prevent the maturation of the egg and do not allow it to be fertilized. What else is included in Lindinet 20? Feedback will be provided below.

Ethinylestradiol

Ethinylestradiol is a highly effective component belonging to the group of estrogens. It is produced by the adrenal glands and ovaries and has an estrogenic effect. In combination with progesterone, ethinyl estradiol regulates the menstrual cycle, provokes the reproduction and division of endometrial cells and has a stimulating effect on the development of secondary sexual characteristics and the uterus in case of their insufficiency. In addition, this type of hormone is able to mitigate or completely eliminate complications due to gonadal dysfunction and lower blood cholesterol levels. This confirms the instructions for use for Lindinet 20 and 30. Analogies are of interest to many.

Gestodene

Second active ingredient drug - gestodene. It is a synthetic progestin, which is similar in structure to levonorgestrel, but surpasses it in selectivity and potency. It inhibits the synthesis of luteotropin and follitropin by the pituitary gland, while blocking ovulation.

In addition to such effects as blocking the fertilization of the egg, the contraceptive effect is due to a decrease in the sensitivity of the uterine endometrium to the blastocyst and an increase in the viscous properties of the mucus in the cervix, which creates an obstacle to the passage of spermatozoa through it. Regular intake of Lindinet 20 for a certain time, according to gynecologists, contributes to the regulation of the menstrual cycle, reduces the risk of pathologies of the woman's reproductive organs, including neoplasms.

The drug should be prescribed by a doctor based on the collected history and taking into account the individual characteristics of the patient.

Contraindications

The drug is contraindicated for use in patients with the following manifestations:

Individual intolerance to the components of the drug or hormones in a certain combination.
Tendency or presence of factors that can lead to venous thrombosis.
Ischemia as a precursor of thrombosis.
Irregular hypertension.
Damage to arteries and veins by thrombosis and thromboembolism.
Frequent migraines associated with disorders of a neurotic nature.
The operation and, as a result, a prolonged lack of motor activity.
Blockage of the veins of the next of kin (thromboembolism).
dyslipidemic syndrome.
Angiopathy of a diabetic nature (as a consequence of diabetes mellitus).
Severe liver damage.
cholelithiasis.
Neoplasms in the liver.
Pigmentary hepatosis (only some forms).
Yellowness of the skin as a result of taking steroid drugs.
Otospongiosis, severe itching.
Vaginal bleeding.
Pathological inflammatory processes in the pancreas with an increase in triglycerides in the blood.
Smoking, especially over the age of 35.
Tumors of the mammary glands and organs of the female reproductive system.
Lactation.
Pregnancy.

How to take "Lindinet 20"? Reviews confirm that this should be done only after consulting with a specialist.

Cautious reception

With caution, you should drink the drug in the following situations:

Development of azotemia, thrombocytopenia and hemolytic anemia (hemolytic uremic syndrome).
Diseases of the liver.
Quincke's edema due to a genetic factor.
Conditions that increase the risk of thromboembolic or thrombotic damage to the arteries and veins, such as age over 35, heredity, or smoking.
Diseases manifested during pregnancy, as well as against the background of taking other hormonal drugs: chloasma, herpes, porphyria, rheumatic chorea.
Obesity.
Hypertension.
Migraines of a regular nature.
Dyslipoproteinemic syndrome.
Seizures.
Dysfunction of the heart valves.
A state of prolonged immobility.
Severe injuries.
Extensive operations.
Atrial fibrillation.

What other restrictions does the instructions for use indicate to Lindinet 20?

Superficial thrombophlebitis of veins and varicose veins.
postpartum period.
Depression.
Biochemical changes in blood composition.
Systemic lupus erythematosus (Libman-Sachs disease).
Diabetes mellitus that does not affect blood vessels.
Granulomatous enteritis.
Liver diseases in acute and chronic form.
Anemia (sickle cell).
Inflammatory processes in the large intestine on the background of an ulcer.
Elevated levels of triglycerides (lipids based on glycerol) in the blood.

Side effects

Birth control pills Lindinet 20, according to reviews, is usually well tolerated. But there are still side effects.

The drug is completely canceled with the following symptoms: porphyria, hypertension, hearing loss as a result of otospongiosis and hemolytic-uremic syndrome.

The following pathologies are rare: thromboembolism of the arteries and veins of the circulatory system, lower extremities, brain, lungs, as well as aggravation of lupus erythematosus (Libman-Sachs disease).

The most rare are thromboembolism of the arteries and veins of the liver, mesentery of the retina, kidneys and chorea. This is confirmed by the "Lindinet 20" instructions for use and reviews.

Frequent manifestations

Common side effects include:

On the part of the reproductive system: the absence of menstrual bleeding after discontinuation of the drug, irregular vaginal hemorrhages and discharge, decreased libido, vaginal inflammation, changes in the state of mucus.
Discomfort, enlargement, soreness and galactorrhea of the mammary glands.
On the part of the digestive system: diarrhea, vomiting, nausea, granulomatous enteritis, pain in the epigastric region, ulcerative inflammatory process in the colon, vdenomatous liver damage, hepatitis, liver dysfunction, bile stasis and cholelithiasis.
Allergic reactions: rashes, erythema, alopecia, increased pigmentation.
From the side of the central nervous system: migraines, depression, headaches and emotional lability.
Weight gain and fluid retention, hyperglycemia, hypertriglyceridemia, decreased tolerance and absorption of carbohydrate compounds by the body as a result of changes in metabolism.
Decreased hearing function, feeling of discomfort when wearing contact lenses.
Hypersensitivity.

There are a lot of reviews of gynecologists about Lindinet 20.

special instructions

When deciding to take an oral contraceptive, you need to take into account the following features:

1. Lactation and pregnancy are absolute contraindications for taking.

2. Before prescribing a medication, the doctor needs to collect comprehensive information about the health of the patient and immediate family. Twice a year, you need to undergo a gynecological and medical examination to eliminate the risk of contraindications and complications.

3. Studies have accurately proven the high contraceptive effectiveness of Lindinet 20, since during the year of use, pregnancy out of 100 women occurred in 0.05 percent of cases.

4. The maximum contraceptive effect is achieved two weeks after the start of taking the pills, so during this period there is a need to use additional funds non-hormonal contraception.

5. The drug is prescribed taking into account the individual characteristics of the patient's body. The specialist evaluates the feasibility and necessity of prescribing Lindinet 20, informing the patient about possible side effects. While taking hormonal drugs, regular gynecological control is necessary. This describes the instructions for Lindinet 20. Reviews of gynecologists are given below.

6. There are situations when it is necessary to completely abandon the use of hormonal contraceptives and switch to other contraceptives. These complications include: convulsions, impaired hemostasis and, as a result, the development of problems in the circulatory system and kidneys, migraines, diabetes mellitus, depression, a poor blood test for biochemistry, anemia and high risk the appearance of a neoplasm due to the intake of hormones.

7. A scientifically proven fact is the relationship between taking hormonal drugs and the development of blood clots and thromboembolism in different systems and organs.

8. The risk of thrombosis and thromboembolism is especially high with the following factors: the patient's age is over 35 years old, genetic predisposition, smoking, obesity, atrial fibrillation, hypertension, heart valve pathology, etc.

9. In the postpartum period, the risk of thromboembolism is significantly increased.

10. Deviations of biochemical parameters of blood from the norm increase the risk of developing thromboembolism of veins and arteries. Bringing the indicators back to normal reduces the likelihood of the disease. The most common symptoms of thromboembolism are: shortness of breath, pain in the retrosternal region, radiating to the left arm, headaches that provoke visual impairment, dizziness, speech disorder, epilepsy, heart failure, numbness and weakness of the body, acute abdomen, pain in the calf muscle.

11. Studies have shown that taking hormonal contraceptives increases the risk of developing cervical cancer. The same applies to the development of breast cancer.

12. Oral hormonal contraceptives do not protect against contracting sexually transmitted infections.

13. The appearance of pain in the abdomen against the background of long-term use of Lindinet 20 may indicate the development of a neoplasm (benign or malignant), which may be a sign of hepatomegaly or bleeding into the abdominal cavity.

14. The effect of taking the drug may decrease against the background of a missed pill, diarrhea, vomiting, improper combination with other drugs.

15. While taking a contraceptive with drugs that reduce the contraceptive effect, it is necessary to use additional methods of contraception. There are reviews of gynecologists about this. Lindinet 20 may not be up to the task.

16. A common complication during pregnancy is chloasma. It can also occur while taking oral contraceptives. If such a probability is not excluded, it is necessary to exclude exposure to ultraviolet and sunlight during the reception.

17. Estrogens can affect the kidneys, liver, thyroid and adrenal glands, making changes in test results.

18. After therapy of a liver affected by a virus, Lindinet 20 can be taken only after six months.

19. The effect of the contraceptive may decrease as a result of severe intestinal disorders and vomiting.

20. Smoking at the same time as taking the drug can cause problems with blood vessels, especially after 35 years.

Method of application and dosage of "Lindinet 20"

How to take Lindinet 20 (LS)? Reviews confirm that there is nothing complicated in this.

The drug is taken 1 tablet once a day, it is undesirable to change the time of admission. After three weeks of admission, a week-long break is made, after which a new package begins on the eighth day. During the break between doses of the drug, bleeding begins.

The first tablet should be taken from the first to the fifth day of menstruation. If you switch to Lindinet 20 from another hormonal contraceptive, then the first tablet is taken the next day after the end of the previous drug. When switching from progestin drugs, you can start taking it on any day of the cycle. After removal of the implant, you can start taking the drug the next day, after the injection before the last injection.

During the first week of admission, you will need to use additional methods of contraception to avoid unwanted pregnancy.

The contraceptive effect is maintained even if you miss one pill. This is confirmed by reviews of gynecologists about Lindinet 20.

Lindinet 20 (ethinyl estradiol + gestodene) is a monophasic tablet combined (estrogen + progestogen) contraceptive. The manufacturer is the Hungarian pharmaceutical company Gedeon Richter. Date of entry into the world market - 2004. The drug is valued for its ability to provide reliable contraception and effectively control the menstrual cycle. Lipdinet 20 is well tolerated, does not affect performance blood pressure and the concentration of aldosterone, which is especially important for women in premenopausal and menopause. Lindinet 20 is also an excellent choice for women of middle reproductive age (from 22 to 35 years old) who need long-lasting, reliable and safe contraception, as well as for girls who are just starting to use hormonal contraceptives. Despite the low content active ingredients, the drug reliably controls the menstrual cycle and is guaranteed to eliminate the characteristic pain lower abdomen. Lindinet 20 is the best choice in cases where a woman has developed unwanted effects caused by a high dose of the estrogen or progestin component. Lindinet 20 contains in its composition the minimum dose of ethinyl estradiol and a progestogen (gestodene), which ensures a rapid drop in plasma estrogen concentration. Gestodene is included in the drug at a dose that does not have clinically significant glucocorticoid activity, which helps maintain a stable body weight.

This is confirmed by studies of the drug, demonstrating the absence of a significant increase in women's body weight. Gestodene is one of the most potent and highly selective progestins on the market today. Due to its high activity, this substance is used in low concentrations, in which it does not affect the metabolism of fats and carbohydrates and does not exhibit androgenic properties. In addition to contraception, the drug also has a therapeutic effect, preventing the development of a number of gynecological diseases, incl. tumor etiology.

Before using Lindinet 20, a woman should undergo a medical examination, including the collection of family and personal anamnestic data, blood pressure measurement, laboratory tests, and a gynecological examination. In the future, such an examination, provided that the woman takes oral contraceptives, should be carried out at intervals of 1 time in six months. Before starting contraceptive therapy using hormonal contraceptives for each woman, all possible benefits and potential risks are weighed, after which the doctor, together with the woman, makes a joint decision on the choice of one or another method of contraception. If, after the start of taking the drug, a woman develops or worsens the disease circulatory system, cardiovascular disease, epilepsy, diabetes mellitus, depression, then contraceptive therapy should be discontinued.

Pharmacology

Monophasic oral contraceptive. It inhibits the secretion of gonadotropic hormones from the pituitary gland. The contraceptive effect of the drug is associated with several mechanisms. The estrogenic component of the drug is ethinylestradiol, a synthetic analogue of the follicular hormone estradiol, which, together with the corpus luteum hormone, participates in the regulation of the menstrual cycle. The progestogen component is gestodene, a derivative of 19-nortestosterone, which is superior in strength and selectivity of action not only to the natural corpus luteum hormone progesterone, but also to other synthetic progestogens (for example, levonorgestrel). Due to its high activity, gestodene is used in low dosages, in which it does not exhibit androgenic properties and has practically no effect on lipid and carbohydrate metabolism.

Along with the indicated central and peripheral mechanisms that prevent the maturation of an egg capable of fertilization, the contraceptive effect is due to a decrease in the susceptibility of the endometrium to the blastocyst, as well as an increase in the viscosity of the mucus in the cervix, which makes it relatively impassable for spermatozoa. In addition to the contraceptive effect, the drug, when taken regularly, also has a therapeutic effect, normalizing the menstrual cycle and helping to prevent the development of a number of gynecological diseases, incl. tumor nature.

Pharmacokinetics

Gestodene

Suction

After oral administration, it is rapidly and completely absorbed from the gastrointestinal tract. After a single dose, Cmax is noted after 1 hour and is 2-4 ng / ml. Bioavailability - about 99%.

Distribution

Gestodene binds to albumin and sex hormone-binding globulin (SHBG). 1-2% is in plasma in free form, 50-75% specifically binds to SHBG. An increase in the level of SHBG in the blood caused by ethinyl estradiol affects the level of gestodene: the fraction associated with SHBG increases and the fraction associated with albumin decreases. Average V d - 0.7-1.4 l / kg. The pharmacokinetics of gestodene depends on the level of SHBG. The concentration of SHBG in the blood plasma under the influence of estradiol increases by 3 times. With daily intake, the concentration of gestodene in the blood plasma increases by 3-4 times and in the second half of the cycle reaches a state of saturation.

Metabolism and excretion

Gestodene is biotransformed in the liver. The average plasma clearance is 0.8-1 ml / min / kg. The level of gestodene in the blood serum decreases biphasically. T 1/2 in the β-phase - 12-20 hours. Gestodene is excreted only in the form of metabolites, 60% in the urine, 40% in the feces. T 1/2 metabolites - about 1 day.

Ethinylestradiol

Suction

After oral administration, ethinylestradiol is absorbed rapidly and almost completely. Average Cmax in blood serum is achieved 1-2 hours after ingestion and is 30-80 pg / ml. Absolute bioavailability due to presystemic conjugation and primary metabolism is about 60%.

Distribution

Completely (about 98.5%), but non-specifically binds to albumin and induces an increase in the level of SHBG in the blood serum. Average V d - 5-18 l / kg.

C ss is set to 3-4 days of taking the drug, and it is 20% higher than after a single dose.

Metabolism

It undergoes aromatic hydroxylation with the formation of hydroxylated and methylated metabolites, which are present in the form of free metabolites or in the form of conjugates (glucuronides and sulfates). Metabolic clearance from blood plasma is about 5-13 ml.

breeding

Serum concentration decreases biphasically. T 1/2 in the β-phase is about 16-24 hours. Ethinylestradiol is excreted only in the form of metabolites, in a ratio of 2:3 with urine and bile. T 1/2 metabolites - about 1 day.

Release form

Light yellow film-coated tablets, round, biconvex, unlabeled on both sides; on a break of white or almost white color with a light yellow edging.

Excipients: calcium sodium edetate - 0.065 mg, magnesium stearate - 0.2 mg, colloidal silicon dioxide - 0.275 mg, povidone - 1.7 mg, corn starch - 15.5 mg, lactose monohydrate - 37.165 mg.

Shell composition: quinoline yellow dye (D + S yellow No. 10) (E104) - 0.00135 mg, povidone - 0.171 mg, titanium dioxide - 0.46465 mg, macrogol 6000 - 2.23 mg, talc - 4.242 mg, calcium carbonate - 8.231 mg, sucrose - 19.66 mg.

21 pcs. - blisters (1) - packs of cardboard.
21 pcs. - blisters (3) - packs of cardboard.

Dosage

Assign 1 tablet / day for 21 days, if possible at the same time of day. After taking the last tablet from the package, a 7-day break is taken, during which withdrawal bleeding occurs. The next day after a 7-day break (i.e. 4 weeks after taking the first tablet, on the same day of the week), the drug is resumed.

The first tablet of Lindinet 20 should be taken from the 1st to the 5th day of the menstrual cycle.

When switching to Lindinet 20 from another combined oral contraceptive, the first Lindinet 20 tablet should be taken after taking the last pill from the package of another oral hormonal contraceptive, on the first day of withdrawal bleeding.

When switching to Lindinet 20 from drugs containing only progestogen ("mini-pili", injections, implant), when taking "mini-drink", you can start taking Lindinet 20 on any day of the cycle, switch from using an implant to taking Lindinet 20 can be the next day after the removal of the implant, when using injections - on the eve of the last injection. In these cases, additional methods of contraception should be used in the first 7 days.

After an abortion in the first trimester of pregnancy, Lindinet 20 can be taken immediately after the operation. In this case, there is no need to use additional methods of contraception.

After childbirth or after an abortion in the second trimester of pregnancy, the drug can be taken on the 21-28th day. In these cases, additional methods of contraception must be used in the first 7 days. With a later start of taking the drug in the first 7 days, an additional, barrier method of contraception should be used. In the case when sexual contact took place before the start of contraception, before starting the drug, pregnancy should be excluded or the start of the drug should be postponed until the first menstruation.

If withdrawal bleeding does not occur after the end of taking the drug from the second package, then pregnancy should be excluded before continuing to take the drug.

To delay the onset of menstruation, the drug should be continued from a new package without a 7-day break. Menstruation can be delayed as long as necessary until the end of the last pill from the second package. With a delay in menstruation, breakthrough or spotting bleeding may occur. Regular intake of Lindinet 20 can be restored after the usual 7-day break.

Overdose

No severe symptoms have been described after taking the drug in high doses.

Symptoms: nausea, vomiting, in girls - bloody discharge from the vagina.

Treatment: symptomatic therapy is prescribed, there is no specific antidote.

Interaction

The contraceptive activity of Lindinet 20 is reduced when taken simultaneously with ampicillin, tetracycline, rifampicin, barbiturates, primidone, carbamazepine, phenylbutazone, phenytoin, griseofulvin, topiramate, felbamate, oxcarbazepine. The contraceptive effect of oral contraceptives is reduced with the use of these combinations, breakthrough bleeding and menstrual disorders become more frequent. While taking Lindinet 20 with the above drugs, as well as within 7 days after completing the course of taking them, it is necessary to use additional non-hormonal (condom, spermicidal gels) methods of contraception. When using rifampicin, additional methods of contraception should be used within 4 weeks after completion of the course of its administration.

When used simultaneously with Lindinet 20, any drug that increases gastrointestinal motility reduces the absorption of active substances and their level in blood plasma.

Liver enzyme inhibitors (itraconazole, fluconazole) increase plasma levels of ethinylestradiol.

Some antibiotics (ampicillin, tetracycline), preventing the intrahepatic circulation of estrogens, reduce the level of ethinylestradiol in plasma.

With the simultaneous use of Lindinet 20 with St. John's wort (including infusion), the concentration of active substances in the blood decreases, which can lead to breakthrough bleeding, pregnancy. The reason for this is the inducing effect of St. John's wort on liver enzymes, which continues for another 2 weeks after the completion of the course of taking St. John's wort. This combination of drugs is not recommended.

Ritonavir reduces the AUC of ethinylestradiol by 41%. In this regard, during the use of ritonavir, a hormonal contraceptive with a higher content of ethinyl estradiol should be used or additional non-hormonal methods of contraception should be used.

It may be necessary to correct the dosing regimen when using hypoglycemic agents, tk. oral contraceptives may reduce carbohydrate tolerance, increase the need for insulin or oral antidiabetic agents.

Side effects

Side effects requiring discontinuation of the drug

From the side of the cardiovascular system: arterial hypertension; rarely - arterial and venous thromboembolism (including myocardial infarction, stroke, deep vein thrombosis of the lower extremities, pulmonary embolism); very rarely - arterial or venous thromboembolism of the hepatic, mesenteric, renal, retinal arteries and veins.

From the senses: hearing loss due to otosclerosis.

Others: hemolytic uremic syndrome, porphyria; rarely - exacerbation of reactive systemic lupus erythematosus; very rarely - Sydenham's chorea (passing after discontinuation of the drug).

Other side effects are more common but less severe. The expediency of continuing the use of the drug is decided individually after consultation with a doctor, based on the benefit / risk ratio.

On the part of the reproductive system: acyclic bleeding / bloody discharge from the vagina, amenorrhea after discontinuation of the drug, changes in the state of vaginal mucus, the development of inflammatory processes in the vagina, candidiasis, tension, pain, enlargement of the mammary glands, galactorrhea.

On the part of the digestive system: epigastric pain, nausea, vomiting, Crohn's disease, ulcerative colitis, the occurrence or exacerbation of jaundice and / or itching associated with cholestasis, cholelithiasis, hepatitis, liver adenoma.

Dermatological reactions: erythema nodosum, erythema exudative, rash, chloasma, increased hair loss.

From the side of the central nervous system: headache, migraine, mood lability, depression.

From the sensory organs: hearing loss, increased sensitivity of the cornea (when wearing contact lenses).

On the part of metabolism: fluid retention in the body, change (increase) in body weight, decreased carbohydrate tolerance, hyperglycemia, increased TG levels.

Other: allergic reactions.

Indications

Contraception.

Contraindications

the presence of severe and / or multiple risk factors for venous or arterial thrombosis (including complicated lesions of the valvular apparatus of the heart, atrial fibrillation, diseases of the cerebral vessels or coronary arteries, severe or moderate arterial hypertension with blood pressure ≥ 160/100 mm Hg .st.);
the presence or indication in the anamnesis of the precursors of thrombosis (including transient ischemic attack, angina pectoris);
migraine with focal neurological symptoms, incl. in history;
venous or arterial thrombosis / thromboembolism (including myocardial infarction, stroke, deep vein thrombosis of the lower leg, pulmonary embolism) at present or in history;
the presence of venous thromboembolism in history;
surgery with prolonged immobilization;
diabetes mellitus (with angiopathy);
pancreatitis (including history), accompanied by severe hypertriglyceridemia;
dyslipidemia;
severe liver disease, cholestatic jaundice (including during pregnancy), hepatitis, incl. in history (before the normalization of functional and laboratory parameters and within 3 months after their normalization);
jaundice when taking GCS;
cholelithiasis at present or in history;
Gilbert's syndrome, Dubin-Johnson syndrome, Rotor's syndrome;
liver tumors (including history);
severe itching, otosclerosis or its progression during a previous pregnancy or taking corticosteroids;
hormone-dependent malignant neoplasms of the genital organs and mammary glands (including if they are suspected);
vaginal bleeding of unknown etiology;
smoking over the age of 35 (more than 15 cigarettes per day);
pregnancy or suspicion of it;
lactation period;
hypersensitivity to the components of the drug.

With caution, the drug should be prescribed in conditions that increase the risk of developing venous or arterial thrombosis / thromboembolism: age over 35 years, smoking, hereditary predisposition to thrombosis (thrombosis, myocardial infarction or impaired cerebral circulation at a young age in one of the next of kin), hemolytic-uremic syndrome, hereditary angioedema, liver disease, diseases that first appeared or worsened during pregnancy or against the background of a previous intake of sex hormones (including porphyria, herpes of pregnant women, minor chorea /Sydenham's disease/, Sydenham's chorea, chloasma), obesity (BMI over 30 kg/m2), dyslipoproteinemia, arterial hypertension, migraine, epilepsy, valvular heart disease, atrial fibrillation, prolonged immobilization, extensive surgery, surgery on lower extremities, severe trauma, varicose veins and superficial thrombophlebitis, postpartum period (non-lactating women /21 days after childbirth/; lactating women after the end of the lactation period), the presence of severe depression, (including history), changes in biochemical indicators (resistance of activated protein C, hyperhomocysteinemia, antithrombin III deficiency, deficiency of othein C or S, antiphospholipid antibodies, incl. antibodies to cardiolipin, lupus anticoagulant), diabetes mellitus not complicated by vascular disorders, SLE, Crohn's disease, ulcerative colitis, sickle cell anemia, hypertriglyceridemia (including family history), acute and chronic diseases liver.

Application features

Use during pregnancy and lactation

The drug is contraindicated for use during pregnancy and lactation.

In small quantities, the components of the drug are excreted in breast milk.

When used during lactation, milk production may decrease.

Application for violations of liver function

Contraindicated in violations of liver function.

Application for violations of kidney function

The drug is not recommended for kidney disease.

special instructions

The drug is a reliable contraceptive: the Pearl index (an indicator of the number of pregnancies that occurred during the use of a contraceptive method in 100 women for 1 year), when used correctly, is about 0.05. Due to the fact that the contraceptive effect of the drug from the start of taking is fully manifested by the 14th day, it is recommended to additionally use non-hormonal methods of contraception in the first 2 weeks of taking the drug.

diseases of the hemostasis system;
conditions/diseases predisposing to the development of cardiovascular, renal failure;
epilepsy;
migraine;
the risk of developing an estrogen-dependent tumor or estrogen-dependent gynecological diseases;
diabetes mellitus, not complicated by vascular disorders;
severe depression (if depression is associated with impaired tryptophan metabolism, then vitamin B 6 can be used for correction);
sickle cell anemia, tk. in some cases (for example, infections, hypoxia), estrogen-containing drugs in this pathology can provoke thromboembolism;
the appearance of abnormalities in laboratory tests for assessing liver function.

Thromboembolic diseases

The risk of developing arterial or venous thromboembolic diseases increases:

with age;
when smoking (heavy smoking and age over 35 are risk factors);
if there is a family history of thromboembolic diseases (for example, in parents, a brother or sister). If a genetic predisposition is suspected, it is necessary to consult a specialist before using the drug;
with obesity (BMI over 30 kg / m 2);
with dyslipoproteinemia;
with arterial hypertension;
in diseases of the heart valves, complicated by hemodynamic disorders;
with atrial fibrillation;
with diabetes mellitus complicated by vascular lesions;
with prolonged immobilization, after major surgery, after surgery on the lower extremities, after a severe injury.

In these cases, a temporary discontinuation of the drug is expected (no later than 4 weeks before surgery, and resumed no earlier than 2 weeks after remobilization).

Women after childbirth have an increased risk of venous thromboembolic disease.

It should be borne in mind that resistance to activated protein C, hyperhomocysteinemia, deficiency of proteins C and S, deficiency of antithrombin III, the presence of antiphospholipid antibodies increase the risk of developing arterial or venous thromboembolic diseases.

sudden chest pain that radiates to the left arm;
sudden shortness of breath;
any unusually severe headache that lasts for a long time or appears for the first time, especially when combined with sudden complete or partial loss of vision or diplopia, aphasia, dizziness, collapse, focal epilepsy, weakness or severe numbness of one side of the body, movement disorders, severe unilateral pain in the calf muscle, symptom complex "acute abdomen".

Tumor diseases

Chloasma can develop in women who have a history of this disease during pregnancy. Those women who are at risk of developing chloasma should avoid contact with sunlight or ultraviolet radiation while taking Lindinet 20.

Efficiency

The effectiveness of the drug may decrease in the following cases: missed pills, vomiting and diarrhea, simultaneous use of other drugs that reduce the effectiveness of birth control pills.

If the patient is simultaneously taking another drug that can reduce the effectiveness of birth control pills, additional methods of contraception should be used.

Changes in laboratory parameters

Under the influence of oral contraceptive pills - due to the estrogen component - the level of some laboratory parameters (functional parameters of the liver, kidneys, adrenal glands, thyroid gland, hemostasis indicators, levels of lipoproteins and transport proteins) may change.

Additional Information

After acute viral hepatitis, the drug should be taken after normalization of liver function (not earlier than after 6 months).

With diarrhea or intestinal disorders, vomiting, the contraceptive effect may decrease. Without stopping taking the drug, it is necessary to use additional non-hormonal methods of contraception.

A woman should be warned that the drug does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Influence on the ability to drive vehicles and control mechanisms

Studies on the effect of the drug Lindinet 20 on the ability to drive a car and work machinery have not been conducted.